Jun 28, 2024

Novanta Q2 2024 Earnings Report

Novanta reported financial results for the second quarter of 2024, surpassing expectations for sales, profit, and cash flow.

Key Takeaways

Novanta's Q2 2024 results showed a revenue of $236 million, an adjusted gross profit margin of 47%, adjusted EBITDA of $51 million, and operating cash flow of $41 million. While industrial capital spending markets remain weak, new products have seen increased adoption and medical device end-markets remain strong.

GAAP Revenue was $236 million.

GAAP Net Income reached $13.8 million.

Adjusted Earnings Per Share was $0.73.

Adjusted EBITDA totaled $51 million.

Total Revenue
$236M
Previous year: $230M
+2.7%
EPS
$0.73
Previous year: $0.8
-8.8%
Adjusted EBITDA
$51.1M
Previous year: $51.7M
-1.2%
Gross Profit
$104M
Previous year: $104M
-0.4%
Cash and Equivalents
$98.5M
Previous year: $91.3M
+7.8%
Free Cash Flow
$36.2M
Previous year: $22.9M
+58.1%
Total Assets
$1.4B
Previous year: $1.23B
+13.5%

Novanta

Novanta

Forward Guidance

For the third quarter of 2024, Novanta expects GAAP revenue of approximately $241 million to $244 million. The Company expects Adjusted Gross Profit Margin to be approximately 47.0% to 47.5%. The Company expects Adjusted EBITDA to be in the range of $56 million to $58 million and Adjusted Diluted EPS to be in the range of $0.85 to $0.89. The Company’s guidance assumes no significant changes in foreign exchange rates.

Positive Outlook

  • GAAP revenue of approximately $241 million to $244 million
  • Adjusted Gross Profit Margin to be approximately 47.0% to 47.5%
  • Adjusted EBITDA to be in the range of $56 million to $58 million
  • Adjusted Diluted EPS to be in the range of $0.85 to $0.89